UPDATED Aug 08, 2022
Discover Swiss Pharmaceuticals & Biotech Growth Stocks that are on the SMI. Sorted by forecasted growth, these Pharmaceuticals & Biotech Stocks have higher than expected earnings or sales growth compared to other companies.
| Company | Last Price | 7D Return | 1Y Return | Market Cap | Analysts Target | Valuation | Growth | Div Yield | ||
|---|---|---|---|---|---|---|---|---|---|---|
| SANNSanthera Pharmaceuticals Holding | CHF0.85 | 2.4% | -60.0% | CHF44.2m | CHF5.50 | PB33.3x | E67.5% | n/a | ||
| IDIAIdorsia | CHF14.33 | 23.5% | -36.7% | CHF2.5b | CHF24.92 | PS58x | E60.3% | n/a | ||
| NWRNNewron Pharmaceuticals | CHF1.42 | -0.7% | -36.3% | CHF25.3m | CHF9.25 | PS4.5x | E54.6% | n/a | ||
| BSLNBasilea Pharmaceutica | CHF41.45 | -5.9% | -8.9% | CHF491.1m | CHF68.29 | PS3.3x | E52.8% | 0% | ||
| COPNCosmo Pharmaceuticals | CHF51.80 | 1.6% | -36.2% | CHF848.7m | CHF86.52 | PE24.7x | E48.9% | 1.8% | ||
| ADXNAddex Therapeutics | CHF0.22 | 9.8% | -86.0% | CHF12.0m | n/a | PS4.8x | E36.3% | n/a | ||
| SKANSKAN Group | CHF56.80 | 6.0% | 44.9% | CHF1.3b | CHF86.50 | PE120.3x | E33.5% | 0.4% | ||
| VIFNVifor Pharma | CHF173.00 | 1.6% | 38.6% | CHF11.2b | CHF163.25 | PE76.6x | E28.5% | 1.2% | ||
| LONNLonza Group | CHF563.00 | -2.3% | -21.4% | CHF41.8b | CHF758.25 | PE45.9x | E16.9% | 0.5% | ||
| BANBBachem Holding | CHF65.75 | 3.0% | -46.7% | CHF4.8b | CHF457.40 | PE42.3x | E14.6% | 1.1% | ||
| SFZNSiegfried Holding | CHF690.50 | -1.6% | -23.8% | CHF2.9b | CHF905.78 | PE30.7x | E13.6% | 0.5% | ||
| PPGNPolyPeptide Group | CHF43.16 | -4.1% | -56.4% | CHF1.4b | CHF70.08 | PE31x | E12.3% | 0.6% | ||
| TECNTecan Group | CHF339.40 | 0.9% | -36.7% | CHF4.3b | CHF494.33 | PE35.5x | E11.2% | 0.8% | ||
| ROGRoche Holding | CHF315.85 | 0.1% | -12.8% | CHF261.0b | CHF374.13 | PE17.7x | E7.5% | 2.9% | ||
| NOVNNovartis | CHF82.28 | 0.7% | -2.8% | CHF179.6b | CHF92.42 | PE8.2x | E3.5% | 3.6% | ||
| MOLNMolecular Partners | CHF6.30 | 3.4% | -64.6% | CHF204.8m | CHF26.47 | PE1.9x | E-73.5% | n/a |